FDA Advisers Back a Multi-Cancer Blood Test: What the Vote Does and Does Not Mean

An Instagram post from ABC News says independent health advisers have endorsed a blood test that may spot signs of many cancers before symptoms start. Verdict: accurate; two details need care. The effectiveness vote was only 6 to 4, and a panel vote is not an approval. This page explains what happened, what the vote does and does not mean, and what is still unknown.

What happened

On September 23, 2026, the Molecular and Clinical Genetics Devices Panel of the FDA's Medical Devices Advisory Committee met about the Galleri test, made by GRAIL. FDA's voting questions asked three things about the test as the company proposed to have it indicated. Was there "reasonable assurance that Galleri is safe"? The panel voted 10 to 0 yes. Was there "reasonable assurance that Galleri is effective"? The vote was 6 to 4 yes. Do "the benefits of Galleri outweigh the risks"? The vote was 7 to 2 yes, with one abstention. (The vote counts come from GRAIL, the Associated Press and CancerNetwork, not from FDA.) The proposed indication is screening for the early detection of multiple types of cancer in adults aged 50 years or older, as a prescription-only test performed at GRAIL. FDA's own panel questions also asked the advisers whether the data support the word "early" and whether more studies should follow approval.

News reports describe a narrower picture than the headline. The Associated Press, in a story carried by ABC News, said the panel raised many questions about the technology that need more study.

What is a multi-cancer early detection test?

A multi-cancer early detection (MCED) test looks at a blood sample for a signal that may point to cancer. Galleri, per ABC's report, does not diagnose cancer. With a single blood draw, it looks for a signal that someone may have one of a long list of cancers, reported as more than 50 types. If it finds a signal, it also tries to predict where in the body the signal comes from. For a plain-language introduction, see Can multi-cancer blood tests find cancer before symptoms begin?.

What an advisory vote is, and is not

An FDA advisory committee is a group of outside experts. The FDA asks them to review data and give their opinion. Their votes are advice.

• The FDA is not bound by the committee's recommendation. It takes the vote into consideration.
• A vote in favor is not an approval. GRAIL submitted its premarket approval application on January 29, 2026 (FDA's briefing document confirms the date), and the final decision on that application remains with the FDA.
• The Galleri test is not FDA-approved today. It is offered as a laboratory-developed test, as we explained in our earlier claim check on Galleri.

The timeline

Sources describe the FDA's final decision as expected "in the coming months." The ABC post says early 2027. That date is the company's own expectation: in reporting before the meeting, GRAIL's chief executive said the company expects approval "in the first part of 2027." We read FDA's meeting page, Federal Register meeting notice, briefing document and panel questions and found no FDA-stated decision date. We also did not find an FDA-published vote record. Timelines can shift.

What the trials showed, and what they did not

These figures appear in FDA's briefing document for the panel (which presents the studies' data as submitted by the company) and in trade-press reporting. They are not final regulatory findings.

• Few false positives. FDA's briefing document reports specificity of 99.85% in the PATHFINDER 2 study and 99.74% in the NHS-Galleri study. Specificity is how often people without cancer correctly get a negative result. "Few false positives" is a fair summary of that number.
• A positive result is not a diagnosis. Reports say how often a positive result turned out to be cancer differs by source and by how it is counted, so we do not put a single number on it. FDA's briefing document says that in PATHFINDER 2, most participants who had a diagnostic evaluation after a positive result had at least one invasive procedure. That raised concern about extra testing when the signal is a false alarm.
• Many cancers are missed. The AP story said the test missed roughly two-thirds of cancers diagnosed within a year. Sensitivity is how often the test finds a cancer that is there.
• The main goal of the big UK trial was not met. Trade reports say NHS-Galleri did not show a statistically significant drop in late-stage (stage III and IV) cancers across its 12 pre-specified cancer types, and that it showed fewer stage IV diagnoses in later screening rounds. FDA's briefing document reports a 3% or 13% lower stage IV rate in the first screening round (all routinely staged cancers, or the 12 pre-specified types) with no formal statistical testing, and says the proposed indication makes no claim about reducing stage IV cancers. Whether the test lowers deaths from cancer has not been shown in these data. The AP story said the panel raised the lack of data on reduced cancer deaths.

The effectiveness vote, six to four, was the narrowest of the three. Trade reporting linked this to how hard it is to judge a screening test in people without symptoms, and to the UK trial result.

A negative result is not an all-clear

The ABC post says a negative result does not mean you are all clear. The AP story reported that the panel called for warnings that the test should add to, not replace, routine screening, and that a negative result does not rule out disease. It also quoted a consumer advocate's concern that people with symptoms might delay seeing a doctor after a negative result. GRAIL's release likewise says the test is meant to be used in addition to, not instead of, guideline-recommended screenings.

Mammograms, colonoscopies, cervical cancer screening and low-dose lung CT for eligible people remain the tests with long track records. Our screening overview explains them. Any new symptom is worth mentioning to a health care team, whatever a blood test says.

What is new here

Our earlier posts covered the science and the cautions: what is known about multi-cancer blood tests, what MCED tests are, the ads for Galleri, and false positives and standard screening. What is new is the advisory step: an FDA panel has now weighed in, by a split vote, and an FDA decision is expected in the coming months.

Where this leaves things

An advisory vote is a step in a review, not the end of one. The test is not yet FDA-approved. Its benefit for lowering cancer deaths is still unproven, and it can miss cancers and raise false alarms. For any personal decision about testing, a clinician who knows your history is the right person to talk with. To read news like this with care, see how to evaluate cancer statistics and news headlines.

Sources

• ABC News / Associated Press, "FDA panel endorses first-of-a-kind cancer blood test from Grail": https://abcnews.com/Technology/wireStory/fda-panel-endorses-kind-cancer-blood-test-grail-136683871
• GRAIL press release on the advisory committee vote: https://grail.com/press-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test/
• Targeted Oncology: https://www.targetedonc.com/view/fda-panel-galleri-multi-cancer-early-detection-test
• AllSci: https://allsci.com/news/development/galleri-cancer-detection-test-fda-approval/
• MedTech Dive: https://medtechdive.com/news/fda-sets-advisory-panel-for-galleri-multicancer-screening-test/827349
• ABC News Instagram post: https://www.instagram.com/reel/DdsBKZXDcob/

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.